WO2023187348A1 - Préparation de particules de biopolymère fonctionnalisées - Google Patents

Préparation de particules de biopolymère fonctionnalisées Download PDF

Info

Publication number
WO2023187348A1
WO2023187348A1 PCT/GB2023/050786 GB2023050786W WO2023187348A1 WO 2023187348 A1 WO2023187348 A1 WO 2023187348A1 GB 2023050786 W GB2023050786 W GB 2023050786W WO 2023187348 A1 WO2023187348 A1 WO 2023187348A1
Authority
WO
WIPO (PCT)
Prior art keywords
biopolymer
solvent
particles
dispersed phase
various embodiments
Prior art date
Application number
PCT/GB2023/050786
Other languages
English (en)
Inventor
Davide CALIFANO
Original Assignee
Naturbeads Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naturbeads Ltd filed Critical Naturbeads Ltd
Publication of WO2023187348A1 publication Critical patent/WO2023187348A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose
    • C08L1/04—Oxycellulose; Hydrocellulose, e.g. microcrystalline cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/02—Oxycellulose; Hydrocellulose; Cellulosehydrate, e.g. microcrystalline cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • C12N11/12—Cellulose or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida

Definitions

  • the present disclosure relates generally to methods for preparing biopolymer particles, and more particularly, to methods for preparing functionalised biopolymer particles.
  • the functionalised biopolymer particles are suitable for, but not limited to, the immobilisation of enzymes for use in applications requiring enzyme catalysis while having improved environmental characteristics.
  • the present disclosure also provides functionalised biopolymer particles obtained by the inventive methods and uses thereof.
  • Biopolymers are an important development in the reduction of the environmental footprint of consumer products. Biopolymers and biopolymer particles are often biodegradable as well as being derived from renewable and sustainable raw materials.
  • the enzymes used for such processes are typically immobilised on a polymer substrate such as acrylic or polystyrene beads.
  • a polymer substrate such as acrylic or polystyrene beads.
  • the bead form factor facilitates mixing during reaction and easy separation from the end products.
  • Synthetic polymers such as acrylic or polystyrene are mainly derived from petroleum and gas as raw materials, meaning that they are incompatible with the environment and reliant on an unsustainable resource. Polymer particles in particular, pose serious ecological problems because they often remain in ecosystems following disposal of the product.
  • Biopolymer particles may therefore be an attractive alternative to synthetic polymer supports in industrial processes such as biocatalysis to realise further environmental and safety benefits.
  • a high degree of immobilisation of the catalyst such as an enzyme should be achieved.
  • enzymes are generally costly reagents, it will usually be desirable for the immobilised enzyme and support to be amenable to multiple reuse cycles while retaining a high degree of catalytic activity.
  • Biopolymer particles prior to the present disclosure may not meet some or all of these requirements.
  • the present disclosure provides a method for preparing functionalised biopolymer particles, said method comprising the steps of: (i) oxidising the biopolymer particles with an agent to form oxidised biopolymer particles, wherein the degree of oxidation of the oxidised biopolymer particles is less than or equal to about 25%; and (ii) reacting said oxidised biopolymer particles with a compound comprising one or more hydrophobic moieties.
  • the biopolymer is a polysaccharide, preferably cellulose.
  • the cellulose may be selected from the group consisting of virgin, recycled, pulp, and microcrystalline cellulose and combinations thereof.
  • the biopolymer particles are in the form of a hydrogel for step (i) of the method of the first aspect.
  • the biopolymer particles are prepared by extruding a dispersed phase into an anti-solvent to form particles of the biopolymer, wherein the dispersed phase comprises the biopolymer in a solvent, and wherein each of the solvent and anti-solvent comprises water.
  • extruding the dispersed phase into an anti-solvent to form particles of the biopolymer comprises extruding the dispersed phase through a fluid medium into a mould and then contacting the extruded dispersed phase with the anti-solvent.
  • the biopolymer particles are prepared by a method comprising (a) a membrane emulsification of a dispersed phase into a continuous phase wherein the dispersed phase comprises the biopolymer in a solvent, and wherein passing the dispersed phase through the membrane forms an emulsion of the biopolymer in the continuous phase; and (b) a phase inversion with an anti-solvent to form particles of the biopolymer; wherein each of the solvent and anti-solvent comprises water.
  • the solvent of the dispersed phase further comprises an ionic liquid.
  • the anti-solvent is substantially free of organic solvents.
  • the anti-solvent may further comprise an ionic liquid.
  • the anti-solvent consists of water.
  • step (i) of the method of the first aspect is conducted at room temperature.
  • the oxidising agent may be selected from the group consisting of periodic acid and salts thereof.
  • the compound comprising one or more hydrophobic moieties may be a hydrocarbyl amine, preferably a primary hydrocarbyl amine.
  • Step (ii) of the method of the first aspect may further be conducted at room temperature.
  • the method of the first aspect further comprises the step of
  • step (iii) reducing the biopolymer particles of step (ii) with a reducing agent.
  • the hydrocarbyl amine is a hydrocarbyl diamine, preferably wherein each amine group of the diamine is a primary amine.
  • the hydrocarbyl diamine may be selected from the group consisting of C6-C14 hydrocarbyl diamines, preferably from the group consisting of Ce-C hydrocarbyl diamines.
  • the method of the first aspect further comprises the step of
  • the enzyme may be a lipase, preferably selected from the group consisting of Candida antartica lipase B, Thermomyces lanuginosus lipase, and Pseudomonas cepacia lipase.
  • the enzyme is immobilised on the biopolymer particle.
  • the present disclosure provides functionalised biopolymer particles obtained by the methods described herein. Features described herein in the context of the methods are also therefore applicable to the functionalised biopolymer particles obtained by the methods.
  • the functionalised biopolymer particles are approximately spherical. In various embodiments the functionalised biopolymer particles have a diameter from about 0.2 mm to about 3 mm.
  • the present disclosure provides for the use of the functionalised biopolymer particles obtained by the methods described herein for immobilising an enzyme.
  • the functionalised biopolymer particles obtained by the methods described herein for immobilising an enzyme.
  • the present disclosure provides a method for performing an enzyme-catalysed reaction wherein the enzyme catalysing the reaction is immobilised on functionalised biopolymer particles prepared by the methods described herein.
  • the enzyme catalysing the reaction is immobilised on functionalised biopolymer particles prepared by the methods described herein.
  • the present disclosure provides for the use of enzyme immobilised biopolymer particles prepared by the methods described herein for catalysing a reaction.
  • enzyme immobilised biopolymer particles prepared by the methods described herein for catalysing a reaction.
  • Features described herein in the context of the preparation method and obtained particles are applicable to this use.
  • FIG. 1 is a schematic representation of an embodiment wherein the biopolymer particles are prepared by extruding a dispersed phase into an anti-solvent.
  • Figure 2 contains a schematic representation of an embodiment wherein the biopolymer particles are prepared by membrane emulsification ( Figure 2(a)), and a representation of a further embodiment wherein the emulsion is cooled as described herein ( Figure 2(b)).
  • Figure 3 shows the degree of enzyme adsorption on unmodified cellulose (CNT), dialdehyde-cellulose (DAC10), 1 ,6-diaminohexane aminated (1 ,6 DABs), 1 ,8-diaminooctane aminated (1 ,8 DABs), and 1 ,10-diaminodecane aminated (1 ,10 DABs) beads for each of Candida antartica lipase B (CaLB), Thermomyces lanuginosus lipase (TL Lipolase), and Pseudomonas cepacia lipase (AMANO PS).
  • the degree of adsorption is determined by measuring the percentage enzyme adsorbed from solution and the mass fraction of enzyme loading after incubation with the beads.
  • Figure 7 is a scanning electron micrograph image of enzyme immobilised, functionalised biopolymer particles prepared from cellulose and (i) 1 ,6-diaminohexane, (ii) 1 ,8- diaminooctane, or (iii) 1 ,10-diaminodecane as described in the Examples herein. Representative images of whole beads, the bead surface, and the internal structure of said beads are shown in each case.
  • the term "about” modifying the quantity of a component refers to variation in the numerical quantity that can occur, for example, through typical measuring and handling procedures used for making concentrates, mixtures or solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the materials employed, or to carry out the methods; and the like.
  • the term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term "about”, the claims include equivalents to the quantities.
  • ranges provided herein provide exemplary amounts of each of the components. Each of these ranges may be taken alone or combined with one or more other component ranges. [0039] As used herein, the term “at least” includes the end value of the range that is specified. For example, “at least 10 cm” includes the value 10 cm.
  • wt% means “weight percentage” as the basis for calculating a percentage. Unless indicated otherwise, all % values are calculated on a weight basis, and are provided with reference to the total weight of the product in which the substance is present.
  • % water in the solvent of the dispersed phase refers to the wt% water based on the total weight of the solvent.
  • % biopolymer in the dispersed phase refers to wt% biopolymer based on the total weight of the dispersed phase.
  • substantially free means no more than trace amounts, i.e. the amount of the substance(s) concerned is negligible. In various embodiments, “substantially free” means no more than 1000 ppm, preferably no more than 100 ppm, more preferably no more than 10 ppm, even more preferably no more than 1 ppm of the substance(s) concerned.
  • the disclosure includes, where appropriate, all enantiomers and tautomers of the compounds disclosed herein.
  • a person skilled in the art will recognise compounds that possess optical properties (one or more chiral carbon atoms) or tautomeric characteristics.
  • the corresponding enantiomers and/or tautomers may be isolated/prepared by methods known in the art.
  • Some of the compounds disclosed herein may exist as stereoisomers and/or geometric isomers - e.g. they may possess one or more asymmetric and/or geometric centres and so may exist in two or more stereoisomeric and/or geometric forms.
  • the present disclosure contemplates the use of all the individual stereoisomers and geometric isomers of those compounds, and mixtures thereof.
  • the terms used in the claims encompass these forms.
  • the general inventive concept is centred on providing a method for preparing functionalised biopolymer particles, where the functionalised biopolymer particles are suitable for use in applications in, but not limited to, biocatalysis, food, biomedicine and pharmaceuticals and have improved environmental benefits.
  • the biopolymer particles of the present disclosure are functionalised by reaction with compounds comprising hydrophobic moieties, which alters the properties of the biopolymers in order to enable or improve their suitability for use in one or more of the above-mentioned applications.
  • the present disclosure provides a method for preparing functionalised biopolymer particles wherein the biopolymer particles are oxidised with an agent to form oxidised biopolymer particles.
  • the oxidation process modifies the nature of the functional groups present in and/or on the biopolymer particles, permitting subsequent functionalisation of the oxidised biopolymer particles.
  • the oxidised biopolymer particles are reacted with a compound comprising one or more hydrophobic moieties.
  • the hydrophobic functionalisation of the biopolymer particles according to the present disclosure confers advantageous physicochemical properties over unmodified biopolymer particles.
  • hydrophobic functionalisation of biopolymer particles according to the methods disclosed herein has been found to enhance the degree of adsorption of enzymes by the particles.
  • enzymes adsorbed in this manner have been found to be more resistant to being washed off during the washing and recycling of the biopolymer particles, leading to enhanced retention of enzymatic activity during multiple re-use cycles.
  • the functionalised biopolymer particles of the present disclosure upon which enzymes have been immobilised exhibit good retention of enzymatic activity during longer periods of storage.
  • the functionalised biopolymer particles exhibit good mechanical stability during preparation and their subsequent use, including during storage and recycling.
  • biopolymer particles By the term “biopolymer” is meant a polymer produced by living organisms. In other words, a polymeric biomolecule. There are three main classes of biopolymers, classified according to the monomeric units used and the structure of the biopolymer formed: polynucleotides (RNA and DNA), which are polymers composed of 13 or more nucleotide monomers; polypeptides, which are polymers of amino acids; and polysaccharides, which are typically polymeric carbohydrate structures. Other examples of biopolymers include rubber, suberin, melanin, chitin and lignin.
  • the biopolymer is selected from the group consisting of polynucleotides, polypeptides and polysaccharides.
  • the biopolymer is selected from the group consisting of polypeptides and polysaccharides.
  • the biopolymer is a polysaccharide, for example, starch, cellulose, chitin, chitosan or glycogen. Even more preferably the biopolymer is starch or cellulose. Most preferably the biopolymer is cellulose.
  • Cellulose is a linear polymer made up of p-D-glucopyranose units covalently linked with 1 ⁇ 4 glycosidic bonds.
  • Cellulose may be obtained from many different sources and the present disclosure is not necessarily limited as to the origin, form, or other characteristics of the cellulose.
  • Cellulose is typically obtained from plant sources, for example from virgin or recycled wood pulp.
  • Pulp is a lignocellulosic fibrous material prepared by chemically or mechanically separating cellulose fibers from wood, fiber crops, waste paper, or rags. Cellulose may be obtained from virgin sources or advantageously from recycled sources.
  • the biopolymer is selected from the group consisting of virgin, recycled, pulp, and microcrystalline cellulose, and combinations thereof.
  • the biopolymer is virgin cellulose.
  • the biopolymer is recycled cellulose.
  • the biopolymer is pulp cellulose.
  • the biopolymer is microcrystalline cellulose.
  • Microcrystalline cellulose is typically made from high-grade, purified wood or cotton cellulose. Hydrolysis is used to remove amorphous cellulose until the microcrystalline form remains. With its amorphous cellulose portions removed, it becomes an inert, white, free- flowing powder. It can be processed in a number of ways, for example through reactive extrusion, steam explosion, and acid hydrolysis.
  • An example of a commercially available MCC is Avicel® produced by DuPont.
  • the term “particle” is used interchangeably herein with “bead” and refers to a discrete solid entity with defined size and shape.
  • the size of the biopolymer particles of the present disclosure is not limited, and the skilled person will be able to select sizes according to a desired application.
  • the size of the particles may be readily identified by a person skilled in the art, for example, using an optical microscope image and image analysis software with a suitable detection algorithm (e.g. Imaged using an edge detection algorithm), laser diffraction with commercially available equipment such as Mastersizer from Malvern Panalytical (e.g. Mastersizer 3000), with an appropriately sized sieve, or by using a caliper.
  • the biopolymer particles are approximately spherical. Approximately spherical biopolymer particles may be advantageous in certain applications, for example in biocatalysis, where such a shape can facilitate industrial processing and recovery processes such as filtration.
  • the particles of beads may have a diameter of at least about 1 pm. In some embodiments, the particles of beads may have a diameter of at least about 10 pm. In some embodiments, the particles of beads may have a diameter of at least about 25 pm. In some embodiments, the particles of beads may have a diameter of at least about 50 pm. In some embodiments, the particles of beads may have a diameter of at least about 100 pm.
  • the particles of beads may have a diameter of less than about 5 mm. In some embodiments, the particles of beads may have a diameter of less than about
  • the particles of beads may have a diameter of less than about
  • the particles of beads may have a diameter of less than about
  • the particles of beads may have a diameter of less than about
  • the functionalised biopolymer particles have a diameter of from about 1 pm to about 3 mm. In various embodiments, the functionalised biopolymer particles have a diameter of from about 10 pm to about 3 mm. In various embodiments, the functionalised biopolymer particles have a diameter of from about 25 pm to about 3 mm. In various embodiments, the functionalised biopolymer particles have a diameter of from about 50 pm to about 3 mm.
  • the functionalised biopolymer particles have a diameter of from about 0.1 mm to about 3 mm. In various embodiments, the functionalised biopolymer particles have a diameter of from about 0.15 mm to about 3 mm. In various embodiments, the functionalised biopolymer particles have a diameter of about 0.20 mm to about 3 mm.
  • the particles or beads may have a diameter greater than or equal to about 0.2 mm. In various embodiments, the particles or beads may have a diameter of from about 0.2 mm to about 3 mm, from about 1 to about 3 mm or from about 1 to about 2 mm.
  • Biopolymer particles may be obtained from various methods of production in a form wherein said particles are wetted or immersed in a solvent such as water. Such particles may be referred to as “wet” beads and may be provided in this form for further use. Alternatively, particles may be subsequently dried to provide “dry beads”. In the present disclosure, it is preferable that the biopolymer particles oxidised in the method of the first aspect have not previously been dried.
  • the biopolymer particles are in the form of a hydrogel for step (i) of the method of the first aspect.
  • a hydrogel is defined by IIIPAC as a gel in which the swelling agent is water.
  • the term “hydrogel” means a non-fluid polymer network (i.e. formed by the biopolymer) that is expanded throughout its whole volume by a fluid, namely water.
  • Biopolymer particles in the form of a hydrogel may be preferred as they can provide a higher effective surface area for reaction in the oxidation step (i) than biopolymer particles that are not in the form of a hydrogel, for example solid particles.
  • An increased effective surface area in turn leads to an increased density of oxidised functional groups for subsequent functionalisation compared to non-hydrogel biopolymer particles.
  • the enhanced effective surface area of the hydrophobically functionalised biopolymer particles may lead to an enhanced degree of adsorption of enzyme on said particles.
  • an enhanced degree of enzymatic activity per particle may be achieved with biopolymer particles in the form of a hydrogel compared to non-hydrogel particles such as solid particles.
  • the oxidation step (i) in the method of the first aspect comprises oxidising the biopolymer particles with an agent to form oxidised biopolymer particles.
  • This agent can be an oxidising agent and the skilled person will be able to select suitable agents capable of oxidising biopolymer particles.
  • the present disclosure is not limited in this respect.
  • Non-limiting examples of agents capable of oxidising biopolymer particles are halogens such as chlorine, hydrogen peroxide, peracetic acid, chlorine dioxide, nitrogen dioxide, persulfate salts, permanganate salts, dichromate-sulfuric acid, hypochlorous acid, hypohalite salts, periodic acid and salts thereof, TEMPO ((2,2,6,6-tetramethylpiperidin-1-yl)oxyl), and transition metal catalysts.
  • the agent for oxidation step (i) is selected from the group consisting of periodic acid and salts thereof.
  • Periodic acid is the highest oxoacid of iodine, with the iodine having an oxidation state of +7.
  • Periodic acid can exist in two forms: orthoperiodic acid (HsIOe) and metaperiodic acid (HIC ), with the same being true of its salts.
  • Salts of periodic acid are known and are not limited in respect of the counterion.
  • the agent is a salt of periodic acid.
  • the salts of periodic acid may be alkali metal salts of periodic acid; for example, sodium periodate or potassium periodate.
  • Periodate oxidation of 1 ,2-diols can lead to carbon-carbon bond cleavage.
  • Such 1 ,2- diols are found in saccharides, such as those constituting the repeat units of polysaccharide biopolymers.
  • periodate oxidation of saccharides can be used to open the saccharide ring leaving two aldehyde groups.
  • the periodate oxidation of 1 ,2-diols is understood to proceed by the following mechanism: wherein M is H or an alkali metal ion.
  • the ring-opening oxidation by periodate may be preferred over radical oxidation such as by TEMPO ((2, 2,6,6- tetramethylpiperidin-1-yl)oxyl).
  • the oxidation may be performed at room temperature (about 20 °C). In various embodiments, the oxidation may be performed in aqueous solution. The use of aqueous conditions may be preferable to reduce environmental impact, to aid in downstream recycling, and to avoid the need to remove traces of solvents that may be undesirable or prohibited for use in downstream applications.
  • the concentration of the oxidising agent may be present in the aqueous solution at a concentration of from about 1 to about 100 mM, from about 10 to about 90 mM, from about 20 to about 80 mM, from about 30 to about 70 mM, or from about 40 to about 60 mM.
  • the extent to which the oxidation reaction is allowed to proceed will determine the degree of oxidation of the biopolymer particles.
  • the degree of oxidation is defined as the mole percentage of generated carbonyl groups relative to the total number of structural repeats in the biopolymer.
  • the degree of oxidation is defined as the mole percentage of carbonyl groups relative to the total amount of anhydrous glucose units in the biopolymer.
  • the skilled person will be able to vary the degree of oxidation as a matter of routine optimisation of the reaction conditions.
  • the degree of oxidation can be determined by titration.
  • the biopolymer is first reacted with hydroxylamine hydrochloride.
  • Aldehyde groups present in the biopolymer will react stoichiometrically (1 :1) with the hydroxylamine hydrochloride to form oxime groups and release hydrochloric acid.
  • the number of moles of hydrochloric acid released is determined by titration with sodium hydroxide, with the number of moles of sodium hydroxide used at the equivalence point corresponding directly to the number of moles of aldehyde groups present in the biopolymer.
  • a person skilled in the art will thus be able to select appropriate reaction parameters to achieve the desired degree of oxidation and monitor reaction progress accordingly. For example, reaction progress can be monitored by performing a time course wherein samples of the reaction are taken at regular intervals, quenched, and the degree of oxidation for each time point determined as detailed above. From such a reaction trajectory, the skilled person can readily determine the reaction time required to achieve a desired degree of oxidation.
  • reaction may be performed under mild agitation, for example by use of an overhead stirrer.
  • the oxidised biopolymer particles are washed to remove the oxidising agent.
  • the oxidised biopolymer articles may, for example, be washed with water.
  • the oxidised biopolymer particles may be separated from the solvent between washing steps by sieving. Multiple washing steps may be performed, and the degree of removal of the oxidising agent may be monitored by methods known to a person skilled in the art, for example UV- visible spectrophotometry. The presence of periodate can be quantitatively determined by the measurement of the absorbance at 290 nm.
  • the oxidised biopolymer particles are washed with water until the washed particles are substantially free of oxidising agent.
  • the functional groups, e.g. aldehyde groups, produced by the oxidation step of the method of the first aspect provide useful reactive moieties for further functionalisation of the biopolymer particles.
  • lower degrees of oxidation are preferable in order to facilitate further functionalisation while retaining similar physicochemical properties as the unmodified particles.
  • too high a degree of oxidation may lead to loss of mechanical stability of the particles and disaggregation, which may impair the separability and re-use of the particles in downstream applications.
  • the degree of oxidation of the oxidised biopolymer particles is less than or equal to about 25%. In various embodiments, the degree of oxidation of the oxidised biopolymer particles is less than or equal to about 20%, or less than or equal to about 15%.
  • the degree of oxidation of the oxidised biopolymer particles is at least about 1% or at least about 5%. In various embodiments, the degree of oxidation of the biopolymer particles is from about 1 % to about 25%, from about 1% to about 20%, or from about 1 % to about 15%. In various embodiments, the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the agent for oxidation step (i) is selected from the group consisting of periodic acid and salts thereof and the degree of oxidation of the oxidised biopolymer particles is less than or equal to about 25%, less than or equal to about 20%, or less than or equal to about 15%.
  • the agent for oxidation step (i) is selected from the group consisting of periodic acid and salts thereof and the degree of oxidation of the oxidised biopolymer particles is at least about 1% or at least about 5%.
  • the agent for oxidation step (i) is selected from the group consisting of periodic acid and salts thereof and the degree of oxidation of the biopolymer particles is from about 1% to about 25%, from about 1% to about 20%, or from about 1 % to about 15%. In various embodiments, the agent for oxidation step (i) is selected from the group consisting of periodic acid and salts thereof and the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the oxidised biopolymer particles are reacted with a compound comprising one or more hydrophobic moieties (step (ii)).
  • hydrophobic takes its usual meaning in the art, namely something that is seemingly repelled from a mass of water.
  • the terms “hydrophobic moiety” and “hydrophobic group” may be used interchangeably in the present disclosure.
  • Hydrophobic moieties have a tendency to associate in an aqueous environment due to the exclusion of nonpolar molecules.
  • Non-limiting examples of hydrophobic moieties include aryl, alkyl, cycloalkyl, aralkyl or alkenyl groups.
  • the compound comprising one or more hydrophobic moieties may, in some embodiments be a hydrocarbyl amine. In such embodiments, it will be understood by a person of ordinary skill in the art that the hydrophobic moiety is the hydrocarbyl group.
  • hydrocarbyl refers to a group comprising at least C and H. If the hydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain heteroatoms. Suitable heteroatoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen, oxygen, phosphorus and silicon.
  • Non-limiting examples of such hydrocarbyls are alkyl groups, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, and isomeric forms thereof; cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloocytyl, 2-methylcyclopentyl, 2,3-dimethyl- cyclobutyl, 4-methylcyclobutyl, 3-cyclopentylpropyl, and the like; cyclo
  • the amine group of the hydrocarbyl amine is able to react with functional groups on the oxidised biopolymer particle surface, such as aldehyde groups.
  • the reaction of amines with aldehydes is known, typically resulting in the formation of an imine.
  • the hydrocarbyl amine when reacted with the oxidised biopolymer particle will generally become covalently attached to the particle.
  • the hydrocarbyl amine may be a primary hydrocarbyl amine.
  • the hydrocarbyl amine is a hydrocarbyl diamine, i.e. a hydrocarbyl group substituted with two amine groups.
  • each hydrocarbyl diamine molecule either or both of the amino groups may react with functional groups on the oxidised biopolymer particle.
  • each amine group of the diamine is a primary amine.
  • the hydrocarbyl group of the hydrocarbyl amine is selected from the group consisting of C6-C14 hydrocarbyl, preferably from the group consisting of Ce-Cw hydrocarbyl.
  • the hydrocarbyl amine is selected from the group consisting of Ce-Ci4 hydrocarbyl amines, preferably from the group consisting of Ce-Cw hydrocarbyl amines.
  • the hydrocarbyl amine is a hydrocarbyl diamine selected from Ce-Ci4 hydrocarbyl diamines, preferably Ce-Cw hydrocarbyl diamines.
  • the hydrocarbyl group of the hydrocarbyl amine is an alkyl group.
  • the hydrocarbyl amine is selected from the group consisting of Ce-Ci4 alkyl amines, preferably from the group consisting of Ce-Cw alkyl amines.
  • the hydrocarbyl amine is an alkyl diamine selected from the group consisting of Ce-Ci4 alkyl diamines, preferably from the group consisting of Ce-Cw alkyl diamines.
  • the alkyl group may preferably be a linear alkyl group.
  • the hydrocarbyl amine is selected from the group consisting of 1 ,6-diaminohexane; 1 ,8-diaminooctane; 1 ,10-diaminodecane; 1 ,12-diaminododecane; and 1 ,14-diaminotetradecane.
  • the hydrocarbyl amine may be selected from the group consisting of 1 ,6-diaminohexane; 1 ,8-diaminooctane; and 1 , 10-diaminodecane.
  • step (ii) is performed in aqueous solution.
  • the solvent for step (ii) is methanol.
  • the oxidised biopolymer particles may be subjected to solvent exchange, for example from water to methanol, before they are reacted with the compound comprising at least one hydrophobic moiety.
  • step (ii) of the method of the first aspect is performed at room temperature (about 20 °C).
  • the reaction time is not limited, and a person skilled in the art will be able to determine a suitable duration for the reaction, for example to ensure that the reaction reaches completion.
  • a molar excess of the compound comprising at least one hydrophobic moiety may be used in the reaction of step (ii).
  • the oxidised biopolymer particles may be reacted with a molar excess of about 1.2, about 1.3, about 1.4, or about 1.5 of the compound comprising one or more hydrophobic moieties.
  • the molar excess is typically calculated on the basis of the amount of oxidised functional groups, e.g. aldehyde groups, present in the oxidised biopolymer articles.
  • step (ii) of the method of the first aspect comprises reacting the oxidised biopolymer particles with at least about 1.2, at least about 1.3, at least about 1.4, or at least about 1.5 molar equivalents (relative to the amount of aldehyde groups) of a hydrocarbyl amine.
  • step (ii) of the method of the first aspect comprises reacting the oxidised biopolymer particles with at least about 1 .2, at least about 1 .3, at least about 1.4, or at least about 1.5 molar equivalents (relative to the amount of aldehyde groups) of a hydrocarbyl diamine, preferably wherein the hydrocarbyl diamine is selected from the group consisting of C6-C14 hydrocarbyl, more preferably wherein the hydrocarbyl diamine is selected from the group consisting of C6-C14 alkyl diamines, even more preferably wherein the hydrocarbyl diamine is selected from the group consisting of 1 ,6-diaminohexane, 1 ,8- diaminooctane, 1 ,10-diaminodecane, 1 ,12-diaminododecane, and 1 , 14-diaminotetradecane.
  • a hydrocarbyl diamine preferably wherein the hydrocarby
  • step (ii) of the method of the first aspect comprises reacting the oxidised biopolymer particles with at least about 1 .2, at least about 1.3, at least about 1.4, or at least about 1.5 molar equivalents (relative to the amount of aldehyde groups) of a hydrocarbyl diamine, preferably wherein the hydrocarbyl diamine is selected from the group consisting of Ce-Cw hydrocarbyl diamines, more preferably wherein the hydrocarbyl diamine is selected from the group consisting of Ce-Cw alkyl diamines, still more preferably wherein the hydrocarbyl diamine is selected from the group consisting of 1 ,6-diaminohexane, 1 ,8- diaminooctane, and 1 ,10-diaminodecane.
  • a hydrocarbyl diamine preferably wherein the hydrocarbyl diamine is selected from the group consisting of Ce-Cw hydrocarbyl diamines, more preferably wherein the
  • the hydrocarbyl amine is selected from the group consisting of Ce-Ci4 hydrocarbyl amines, preferably from the group consisting of Ce-Cw hydrocarbyl amines, and the degree of oxidation of the biopolymer particles is from about 1% to about 25%, from about 1% to about 20%, or from about 1 % to about 15%.
  • the hydrocarbyl amine is selected from the group consisting of C6-C14 alkyl amines, preferably from the group consisting of Ce-Cw alkyl amines, and the degree of oxidation of the biopolymer particles is from about 1% to about 25%, from about 1 % to about 20%, or from about 1 % to about 15%.
  • the hydrocarbyl amine is a hydrocarbyl diamine selected from the group consisting of Ce-Ci4 hydrocarbyl diamines, preferably from the group consisting of Ce-Cw hydrocarbyl diamines, and the degree of oxidation of the biopolymer particles is from about 1% to about 25%, from about 1 % to about 20%, or from about 1% to about 15%.
  • the hydrocarbyl diamine is selected from the group consisting of Ce-Ci4 alkyl diamines, preferably from the group consisting of Ce-Cw alkyl diamines, and the degree of oxidation of the biopolymer particles is from about 1 % to about 25%, from about 1 % to about 20%, or from about 1 % to about 15%.
  • the hydrocarbyl amine is selected from the group consisting of C6-C14 hydrocarbyl amines, preferably from the group consisting of Ce-Cw hydrocarbyl amines, and the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the hydrocarbyl amine is selected from the group consisting of Ce-Ci4 alkyl amines, preferably from the group consisting of Ce-Cw alkyl amines, and the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the hydrocarbyl amine is a hydrocarbyl diamine selected from the group consisting of Ce-Ci4 hydrocarbyl diamines, preferably from the group consisting of Ce-Cw hydrocarbyl diamines, and the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the hydrocarbyl diamine is selected from the group consisting of Ce-Ci4 alkyl diamines, preferably from the group consisting of Ce-Cw alkyl diamines, and the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%.
  • the agent for the oxidation step (i) may be selected from the group consisting of periodic acid and salts thereof.
  • the hydrocarbyl diamine may be selected from the group consisting of Ce-Ci4 hydrocarbyl diamines, preferably from the group consisting of Ce-C hydrocarbyl diamines, the degree of oxidation of the biopolymer particles may be from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%, and the agent for oxidation step (i) may be selected from the group consisting of periodic acid and salts thereof.
  • the hydrocarbyl diamine may be selected from the group consisting of 1 ,6-diaminohexane; 1 ,8-diaminooctane; 1 ,10-diaminodecane; 1 ,12- diaminododecane; and 1 ,14-diaminotetradecane, the degree of oxidation of the biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%, and the agent for oxidation step (i) may be selected from the group consisting of periodic acid and salts thereof.
  • the method of the first aspect further comprises the step of reducing the biopolymers of step (ii) with a reducing agent.
  • a reducing agent is not limited, and the skilled person will be able to select reducing agents appropriate to the chemistry of the group(s) being reduced.
  • Non-limiting examples of commonly used reducing agents include sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride.
  • the product of step (ii) will typically be an imine.
  • Subsequent reaction of the imine functionalised biopolymer particles, for example with sodium borohydride leads to reduction of the imine groups to amine groups, such that the hydrophobic moiety (e.g. hydrocarbyl group) will be attached covalently to the biopolymer particles via the amine functionality.
  • Such a linkage may be less labile and more resistant to hydrolysis.
  • the reduction step is performed at room temperature (about 20 °C).
  • the solvent for the reduction step is methanol.
  • the reduction step is performed in aqueous solution.
  • the reduction step may be performed in the same or different solvent as step (ii) of the method of the first aspect.
  • the biopolymer particles may be subjected to solvent exchange, for example by sieving.
  • a molar excess (relative to the number of functional groups on the biopolymer particles to be reduced) of reducing agent may be used.
  • At least about 1.2, at least about 1.5, at least about 1.8, or at least about 2.0 molar equivalents (relative to the amount of carbonyl groups) of reducing agent are used in the reduction step.
  • a higher excess of reducing agent may be preferred when using a reducing agent such as sodium borohydride that is more susceptible to hydrolysis.
  • the reduced biopolymer particles are typically washed to remove all traces of reducing agent.
  • the reduced biopolymer particles are washed with water. Where methanol is used as a solvent, the washing also serves to remove all traces of methanol from the reduced biopolymer particles.
  • the agent for the oxidation step (i) is selected from the group consisting of periodic acid and salts thereof, the degree of oxidation of the oxidised biopolymer particles is from about 1% to about 25%, from about 1% to about 20%, or from about 1% to about 15%, and said method further comprises the step of reducing the biopolymers of step (ii) with a reducing agent.
  • the agent for the oxidation step (i) is selected from the group consisting of periodic acid and salts thereof, the degree of oxidation of the oxidised biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%, and said method further comprises the step of reducing the biopolymers of step (ii) with a reducing agent.
  • the oxidised biopolymer particles are reacted in step (ii) with a hydrocarbyl diamine, preferably wherein the hydrocarbyl diamine is selected from the group consisting of Ce-Cu hydrocarbyl diamines, more preferably from the group consisting of C6-C14 hydrocarbyl diamines, even more preferably from the group consisting of C6-C14 alkyl diamines, and still more preferably from the group consisting of 1 ,6- diaminohexane; 1 ,8-diaminooctane; 1 ,10-diaminodecane; 1 ,12-diaminododecane; and 1 ,14- diaminotetradecane.
  • the hydrocarbyl diamine is selected from the group consisting of Ce-Cu hydrocarbyl diamines, more preferably from the group consisting of C6-C14 hydrocarbyl diamines, even more preferably from the group consisting of C6-C14 alky
  • the agent for the oxidation step (i) is selected from the group consisting of periodic acid and salts thereof, the degree of oxidation of the oxidised biopolymer particles is from about 5% to about 25%, from about 5% to about 20%, or from about 5% to about 15%; the oxidised biopolymer particles are reacted in step (ii) with a hydrocarbyl diamine, preferably wherein the hydrocarbyl diamine is selected from the group consisting of C6-C14 hydrocarbyl diamines, more preferably from the group consisting of C6-C14 hydrocarbyl diamines, even more preferably from the group consisting of C6-C14 alkyl diamines, and still more preferably from the group consisting of 1 ,6- diaminohexane; 1 ,8-diaminooctane; 1 ,10-diaminodecane; 1 ,12-dia
  • the reducing agent may be selected from the group consisting of sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride.
  • the functionalised biopolymer particles of the present disclosure have been found to be particularly suitable as substrates for the immobilisation of enzymes.
  • the method of the first aspect further comprises the step of contacting the reduced biopolymer particles with an enzyme to form enzyme functionalised biopolymer particles.
  • Immobilised enzymes are routinely used for the manufacture of many industrial products, for example in the manufacture of pharmaceuticals, chemicals and foodstuffs.
  • BASF have used the lipase from Candida Antarctica (CalB) to produce chiral compounds such as dimethenamide-P, a herbicide that was previously produced by chemical synthesis.
  • Enzymes can be attractive catalysts in industry as they may be used at lower reaction temperatures and can stereospecifically produce chiral compounds. Moreover, enzymes may have a preferable safety and/or environmental profile over chemical reagents/catalysts. Accordingly, biocatalysis is generally considered a ‘green’ process in comparison to chemical synthesis.
  • immobilisation being a form of heterogeneous catalysis, brings further benefits in terms of simplified downstream processing or continuous process operations. This is because immobilised enzymes can be recovered and reused, often while retaining activity for long periods of time. Enzymes can be expensive to produce at scale and so their recovery and reuse is generally economically preferable. Further, immobilised enzymes are typically amenable to a variety of process configurations, for example in batch stirred reactors as well as in packed bed column reactors.
  • the functionalised biopolymer particles of the present disclosure are particularly useful supports for the immobilisation of enzymes because the biopolymer particles can be produced from renewable and biodegradable feedstock rather than petrochemicals. Further, the biopolymer particles can be produced according to the methods disclosed herein without the use of hazardous or environmentally harmful substances such as organic solvents and which facilitate the re-use and recycling of the process chemicals such as the solvent and antisolvent.
  • Enzymes that may be contacted with the reduced biopolymer particles of the present disclosure are not limited.
  • Non-limiting examples of important categories of industrial enzymes are carbohydrases, proteases and lipases.
  • the reduced biopolymer particles are contacted with an enzyme which is a lipase.
  • Lipases are enzymes that catalyse the hydrolysis of lipids. Many lipases are known and/or commercially available and the selection and/or production of lipases by conventional means is specifically within the common general knowledge of a person skilled in the art.
  • the lipase is purified from a microorganism that endogenously produces said lipase.
  • the lipase is recombinantly produced in a heterologous microorganism.
  • the lipase is selected from the group consisting of Candida antartica lipase B, Thermomyces lanuginosus lipase, and Pseudomonas cepacia lipase, all of which are commercially available, for example from Sigma-Aldrich.
  • the reduced biopolymer particles of the present disclosure may be used for the immobilisation of enzymes.
  • the enzyme upon contacting the reduced biopolymer particles with an enzyme, the enzyme is immobilised on said biopolymer particles, producing what are referred to herein as enzyme functionalised biopolymer particles.
  • non-covalent interactions may include van der Waals interactions, hydrogen bonding, ionic interactions, halogen bonding, pi-effects such as pi-pi, cation-pi or anion-pi interactions, and combinations thereof.
  • the enzyme functionalised biopolymer particles of the present disclosure have been found to exhibit good levels of enzyme immobilisation, and in particular higher levels of adsorption compared with biopolymer particles that have not been functionalised by the methods disclosed herein. Moreover, the enzyme functionalised biopolymer particles of the present disclosure exhibit good retention of enzyme activity after at least two rounds of recycling. For example, in the tests reported in the Examples and Figure 5, CalB immobilised on 1 ,6-diaminohexane functionalised biopolymer particles exhibited generally stable levels of enzyme activity after an initial recycling step and up to the tenth recycling step (Figure 5a).
  • the enzyme functionalised biopolymer particles of the present disclosure also exhibit good storage stability even in the absence of stabilisers and/or preservatives.
  • storage stability refers to the retention of enzyme activity when stored in a solvent or solution, such as water.
  • the enzyme functionalised biopolymer particles of the present disclosure may exhibit less than 50%, less than 40%, or less than 30% loss of enzyme activity after storage in water for at least 1 month, at least 2 months, or at least 3 months.
  • the enzyme functionalised biopolymer particles are stored in water at 4 °C.
  • the enzyme immobilised biopolymer particles are particularly useful for biocatalysis, i.e. they may be used for catalysing a reaction.
  • the present disclosure provides a method for performing an enzyme-catalysed reaction wherein the enzyme catalysing the reaction is immobilised on functionalised biopolymer particles prepared by the methods disclosed herein.
  • the nature of the reaction is not limited, and the skilled person will be able to select enzymes capable of performing the desired chemical transformation.
  • the reaction may be performed in aqueous solution or may be performed in one or more organic solvents.
  • suitable solvent systems and other reaction conditions for performing a biocatalytic reaction is also in the common general knowledge of a person skilled in the art.
  • the present disclosure provides a generally applicable methodology for the functionalisation of biopolymer particles. Accordingly, the present disclosure is not limited in terms of the means by which the biopolymer particles are prepared.
  • biopolymer particles may be prepared by extrusion, and (ii) membrane emulsification followed by phase inversion.
  • a dispersed phase is extruded into an anti-solvent to form particles of the biopolymer.
  • the dispersed phase comprises the biopolymer in a solvent as discussed further below, and the extrusion of such a dispersed phase is known in the art. It is a process wherein the dispersed phase is forced, pressed, or pushed out, for example through an aperture or opening.
  • the opening may be in a syringe as shown in Figure 1 or any other suitable extrusion device as known in the art.
  • FIG. 1 A schematic representation of an exemplary embodiment of the extrusion process is shown in Figure 1.
  • the dispersed phase (1) comprising the biopolymer in a solvent is extruded through a needle (2) of a syringe (3). Extrusion is specifically into the anti-solvent (4) to form biopolymer particles (5).
  • the extruded dispersed phase is dropped from a height, d, above the surface of the anti-solvent.
  • the latter exemplary method of preparing biopolymer particles comprises a membrane emulsification step and a phase inversion step.
  • Membrane emulsification is known in the art; it is a technique in which a dispersed phase is forced through the pores of a microporous membrane directly into a continuous phase, where emulsified droplets are formed and detached at the end of the pores with a drop- by-drop mechanism.
  • a schematic representation of a membrane emulsification process is shown in Figure 2, where the arrow indicates the direction of flow.
  • the dispersed phase generally includes a first liquid containing the biopolymer dissolved in a solvent, and the continuous phase includes a second liquid which is immiscible with the first liquid.
  • the interaction of the two liquids when the dispersed phase is pushed or otherwise transported through the membrane is called a dispersion process, and their inhomogeneous mixture is termed an emulsion, i.e. droplets of the dispersed phase surrounded by the continuous phase.
  • phase inversion is a chemical phenomenon exploited in the fabrication of artificial membranes, and is performed by removing solvent from a liquid-polymer solution.
  • phase inversion includes immersing the polymer solution into a third liquid called the anti-solvent.
  • anti-solvent based phase inversion has proven to be particularly effective in precipitating droplets of biopolymer into particles from an emulsion of dispersed/continuous phase.
  • biopolymer particles Common to both exemplary processes for preparing biopolymer particles is the use of a solvent into which the biopolymer is dissolved to form the dispersed phase, and the use of an anti-solvent to form the biopolymer particles.
  • Ionic liquids are salts that are in liquid form at a temperature between ambient temperature and 100°C, for example imidazolium based ionic liquids such as 1-ethyl-3-methylimidazolium acetate (EmimOAc), 1-butyl-3-methylimidazolium chloride (BmimOAc) or the like.
  • imidazolium based ionic liquids such as 1-ethyl-3-methylimidazolium acetate (EmimOAc), 1-butyl-3-methylimidazolium chloride (BmimOAc) or the like.
  • ionic liquids are essentially non-volatile (avoiding fugitive emissions) and are considered to have environmental benefits over other solvents. Ionic liquids can, for example, be readily recycled by distillation to remove the anti-solvent.
  • Ionic liquids are typically not used in pure form, however.
  • An amount of a co-solvent is often added to the ionic liquid when dissolving biopolymers such as cellulose.
  • the use of a cosolvent may assist in dissolution of the biopolymer, and may reduce the amount of costly ionic liquid required.
  • the inclusion of a co-solvent may also improve the efficiency and yield of the process by modifying the viscosity of the dispersed phase, which may in turn reduce the amount of deformation exhibited by the particles.
  • Typical co-solvents employed in combination with ionic liquids are dipolar aprotic solvents, such as dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and the like.
  • DMSO dimethyl sulfoxide
  • DMF dimethylformamide
  • DMSO dimethyl sulfoxide
  • DMF dimethylformamide
  • Such co-solvents therefore cannot be used in processes for the preparation of biopolymer particles for use in cosmetic and personal care as well as other applications.
  • dipolar aprotic solvents may also complicate the recycling of the ionic liquid and increase costs.
  • some degree of distillation of DMSO is to be expected during recycling and the presence of aprotic solvent has been reported to reduce the thermal stability of 1-ethyl-3-methylimidazolium acetate (EmimOAc) [see Williams et al., Thermochimica Acta (2016), 669 126-139, for example].
  • organic solvents such as ethanol are typical. Again, however, these substances may reduce the overall environmental benefits of the process, may be associated with safety concerns, and may complicate and increase the cost of recycling of ionic liquids.
  • an aqueous solvent and an aqueous anti-solvent may be used.
  • the use of an aqueous solvent and anti-solvent may obviate the use of reagents associated with environmental and safety concerns and may also simplify and reduce the cost of solvent recycling.
  • use of such solvents and anti-solvents may increase the stability of ionic liquids against temperature-based degradation [Williams et al., Thermochimica Acta (2016), 669: 126-139], which may allow an increased number of recycling cycles to be performed, for example.
  • the inclusion of water in the dispersed phase may increase the likelihood of bead sphericity.
  • the dispersed phase from which the biopolymer particles may be prepared comprises a solvent in which the biopolymer is dispersed or dissolved, which solvent comprises water.
  • solvent is therefore meant any substance (e.g. liquid) which disperses or dissolves the biopolymer.
  • solvent also includes solvent mixtures.
  • the solvent of the dispersed phase may comprise water and may comprise an ionic liquid, an organic solvent, an inorganic nonaqueous solvent, or a combination thereof.
  • the solvent for the dispersed phase comprises water and at least one of an ionic liquid, an organic solvent, an inorganic nonaqueous solvent, or a combination thereof.
  • the solvent for the dispersed phase comprises water and one or more ionic liquid(s).
  • Non-limiting examples of solvents for the dispersed phase other than water include methanol, ethanol, ammonia, acetone, acetic acid, n-propanol, n-butanol, isopropyl alcohol, ethyl acetate, dimethyl sulfoxide, sulfuryl chloride, phosphoryl chloride, carbon disulfide, morpholine, N-methylmorpholine, NaOH without and with association of urea and thiourea, bromine pentafluoride, hydrogen fluoride, sulfuryl chloride fluoride, acetonitrile, dimethylformamide, hydrocarbon oils and blends thereof, toluene, chloroform, carbon tetrachloride, benzene, hexane, pentane, cyclopentane, cyclohexane, 1 ,4-dioxane, dichloromethane, nitromethane, propylene carbonate, formic acid,
  • the dispersed phase will depend on the biopolymer being used.
  • suitable solvents for the dispersed phase of the present disclosure is specifically within the common general knowledge of the skilled person.
  • the solvent for the dispersed phase comprises water and an ionic liquid.
  • the ionic liquid may be selected from 1-ethyl-3-methylimidazolium acetate (EmimOAc), 1-butyl-3-methylimidazolium chloride (BmimOAc), and a combination thereof.
  • the solvent for the dispersed phase comprises water and one or more organic solvents.
  • the solvent for the dispersed phase is substantially free of organic solvents. The term “substantially free” is defined above.
  • the solvent of the dispersed phase consists of water and an ionic liquid
  • the total wt% of water and ionic liquid in the dispersed phase solvent will total 100 wt%. If water is present, for example, in an amount of at least 0.5 wt%, an ionic liquid may be present in an amount of at least 99.5 wt%, with the proviso that the total of water and ionic liquid is 100 wt%. In other words, the ionic liquid may be present as the remainder of the solvent.
  • the solvent used for the dispersed phase is environmentally friendly.
  • environmentally friendly is meant not harmful to the environment such that the solvent can be disposed of without the need for specialist equipment or process(es), i.e. non-toxic.
  • polysaccharides have limited dissolution in most of the common solvents.
  • those solvents which do dissolve polysaccharides are often toxic and/or highly selective.
  • the biopolymer is a polysaccharide such as cellulose, starch, chitin, glycogen, and/or chitosan
  • the solvent for the dispersed phase may therefore comprise an ionic liquid in addition to water.
  • the dissolution of cellulose with the ionic liquid 1- butyl-3-methylimidazolium chloride is, for example, discussed in Richard et al., J. Am. Chem. Soc. 2002, 124, 4974-4975. Verma et al., Sustainable Chemistry and Pharmacy 13 (2019), 100162 similarly discusses the solubility of cellulose in ionic liquids and ionic liquids with cosolvents. Each of these disclosures is incorporated herein by reference.
  • the concentration of biopolymer in the dispersed phase is not limited and may be any concentration suitable for the methods discussed herein. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 0.1 wt% to about 15 wt%.
  • the biopolymer is present in the dispersed phase in an amount from about 0.5 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 1 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 1.5 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 2 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 2.5 wt% to about 15 wt%.
  • the biopolymer is present in the dispersed phase in an amount from about 3 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 3.5 wt% to about 15 wt%. In various embodiments the biopolymer is present in the dispersed phase in an amount from about 4 wt% to about 15 wt%.
  • the biopolymer is present in the dispersed phase in an amount from about 0.1 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 0.5 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 1 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 1.5 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 2 wt% to about 12 wt %.
  • the biopolymer is present in the dispersed phase in an amount from about 2.5 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 3 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 3.5 wt% to about 12 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 4 wt% to about 12 wt %.
  • the biopolymer is present in the dispersed phase in an amount from about 0.1 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 0.5 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 1 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 1.5 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 2 wt% to about 10 wt%.
  • the biopolymer is present in the dispersed phase in an amount from about 2.5 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 3 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 3.5 wt% to about 10 wt %. In various embodiments, the biopolymer is present in the dispersed phase in an amount from about 4 wt% to about 10 wt %.
  • the dispersed phase may further include optional components. These optional components include, but are not limited to, surfactants, porogens, active ingredients, pockets of air, double emulsions, pigments, and dyes. The level of any of the optional components is not significant in the present disclosure.
  • the dispersed phase includes a co-solvent.
  • the surfactant may be any suitable surfactant known in the art, for example, any ionic or non-ionic surfactant.
  • Ionic surfactants may include sulfates, sulfonates, phosphates and carboxylates such as alkyl sulfates, ammonium lauryl sulfates, sodium lauryl sulfates, alkyl ether sulfates, sodium laureth sulfate and sodium myreth sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, alkyl benzene sulfonates, alkyl aryl ether phosphates, alkyl ether phosphates, and alkyl carboxylates.
  • Non-ionic surfactants may include polyethers, polyoxyalkylene derivatives of hexitol, partial long-chain fatty acid esters such as sorbitan oleates, ethylene oxide derivatives of long-chain alcohols, ethoxylated vegetable oil, polydimethylsilxoxanes, and ethylene oxide/propylene oxide copolymers.
  • the temperature of the dispersed phase is not limited.
  • temperature of the dispersed phase or “the dispersed phase is at a temperature of”, or the like, is meant the temperature of the dispersed phase prior to extrusion or membrane emulsification (e.g. when it is placed in the apparatus for such extrusion or emulsification), and/or the temperature of the apparatus during extrusion or emulsification of the dispersed phase.
  • the extrusion or emulsification means may be heated so that the dispersed phase remains at an elevated temperature in situ.
  • the extrusion means is heated directly by one or more heating means. This is discussed further below.
  • the dispersed phase is at ambient or room temperature, namely between about 20 and about 25°C. In various embodiments the dispersed phase is heated above ambient temperature.
  • the dispersed phase may be heated using any suitable means.
  • the dispersed phase is preferably heated in situ such that there is no temperature loss prior to extrusion or membrane emulsification, for example by heating a vessel containing the dispersed phase and/or the extrusion or emulsification means. In the extrusion process, a heated syringe and/or needle may, for example, be used.
  • Suitable heating apparatus may comprise a heating element, for example a Peltier element, as well as a means of regulating the temperature, such as a thermocouple and controller.
  • the temperature of the dispersed phase is from about 5°C to less than about 100°C, from about 10°C to less than about 100°C, from about 15°C to less than about 100°C, from about 20°C to less than about 100°C, from about 25°C to less than about 100°C, or from about 30°C to less than about 100°C.
  • the maximum temperature will be set by the point at which the evaporation of water from the dispersed phase becomes prohibitive and/or decomposition of the ionic liquid begins to occur. This will readily be determined by the person skilled in the art.
  • the temperature of the dispersed phase is from about 5°C to about 90°C, from about 10°C to about 90°C, from about 15°C to about 90°C, from about 20°C to about 90°C, from about 25°C to about 90°C, or from about 30°C to about 90°C.
  • the temperature of the dispersed phase is from about 5°C to about 80°C, from about 10°C to about 80°C, from about 15°C to about 80°C, from about 20°C to about 80°C, from about 25°C to about 80°C, from about 30°C to about 80°C, or from about 40°C to about 80°C.
  • the anti-solvent may comprise water, i.e. it may be aqueous.
  • the anti-solvent may comprise water and an organic solvent such as an alcohol or acetone, or any other organic solvent known in the art. Suitable alcohols include ethanol and/or methanol.
  • the anti-solvent is environmentally friendly. More preferably, the solvent and antisolvent are both environmentally friendly.
  • the anti-solvent is substantially free of organic solvents.
  • the anti-solvent is or consists of water.
  • the anti-solvent further comprises an ionic liquid.
  • the anti-solvent may comprise water and an ionic liquid before phase inversion or extrusion of the dispersed phase.
  • the ionic liquid may be introduced into the anti-solvent during the phase inversion or extrusion.
  • the dispersed phase comprises an ionic liquid
  • the ionic liquid may be introduced into the antisolvent from the dispersed phase during the phase inversion or extrusion process.
  • the concentration of ionic liquid in the anti-solvent is up to about 50 wt% - the term “up to” being understood to mean greater than zero. In various embodiments the concentration of ionic liquid in the anti-solvent is up to about 40 wt%. In various embodiments the concentration of ionic liquid in the anti-solvent is up to about 30 wt%. In various embodiments the concentration of ionic liquid in the anti-solvent is up to about 20 wt%. In various embodiments the concentration of ionic liquid in the anti-solvent is up to about 10 wt%.
  • the anti-solvent comprises water and an ionic liquid
  • the ionic liquid may be 1- ethyl-3-methylimidazolium acetate (EmimOAc), 1-butyl-3-methylimidazolium chloride (BmimOAc), or mixtures thereof.
  • the ionic liquid is 1-ethyl-3- methylimidazolium acetate (EmimOAc).
  • the temperature of the anti-solvent is not limited. In various embodiments, the temperature of the anti-solvent is from about 5°C to about 80°C. In various embodiments, the temperature of the anti-solvent is from about 10°C to about 70°C. In various embodiments the temperature of the anti-solvent is from about 15°C to about 60°C.
  • the temperature of the antisolvent may be ambient such that phase inversion is carried out at ambient temperature, namely between about 20 and about 25°C.
  • the anti-solvent has a temperature between about 20 and about 25°C.
  • the anti-solvent is cooled to a temperature below ambient temperature, namely below about 20°C.
  • the anti-solvent may be cooled to a temperature T2, for the phase inversion (b), T2 being less than Tdisp.
  • T2 is substantially equal to T1, more preferably T2 is equal to T1 , where T1 is defined above.
  • the advantage of controlling the temperature of the anti-solvent (T2) in such embodiments is to prevent pre-mature thawing of the frozen droplets.
  • T2 temperature of the anti-solvent
  • the droplets remain in a frozen state (and hence spherical and non-aggregated) whilst the continuous phase surrounding them is stripped away by the phase inversion.
  • the anti-solvent is able to contact the surface of the droplets, causing precipitation of the biopolymer and hardening of the precipitate surface.
  • the anti-solvent will convert the droplet of dissolved biopolymer to a bead/particle thereof, whilst leaching the solvent system into the anti-solvent.
  • biopolymer particles are prepared
  • a non-limiting example of a suitable method is wherein the dispersed phase is extruded into the anti-solvent to form particles of the biopolymer.
  • the dispersed phase is extruded through a fluid medium by capillary extrusion.
  • the fluid medium may, for example, be air.
  • capillaries through which the dispersed phase may be extruded are glass capillaries, microfluidic channels, and (hypodermic) needles.
  • the material from which such capillaries are prepared is not limited and the skilled person will be able to select suitable capillaries compatible with the dispersed phase.
  • the surface of the capillary may also be modified.
  • the capillary may, for example, be treated, coated, or lined, in order to alter its wetting properties.
  • Such modifications of the capillary material may, for example, alter the hydrophilicity/hydrophobicity of the capillary material, thereby altering the wettability of the capillary surface.
  • Capillaries may, for example, be treated with reactive hydrophobic compounds such as silanes to form a hydrophobic surface layer, or hydrophobic compounds may be deposited onto a capillary surface by methods such as chemical vapour deposition.
  • metal needles may be lined with PTFE (polytetrafluoroethylene). The identification of suitable surface modifications is specifically within the common general knowledge of the skilled person.
  • the size of the aperture or opening e.g. the diameter of the capillary or the gauge of the needle, is not limited. It will be immediately apparently to a person skilled in the art that the size of the aperture or opening will, however, influence the size of the droplets of the dispersed phase extruded therefrom. Generally, a larger aperture or opening would be expected to produce larger droplets of the dispersed phase, and conversely a smaller aperture or opening would be expected to produce smaller droplets of the dispersed phase. The skilled person will be able to select appropriately sized openings/apertures.
  • the diameter of the aperture or opening through which the dispersed phase is extruded may be less than about 3 mm, less than about 2.5 mm, less than about 2 mm, less than about 1.5 mm, less than about 1 mm, less than about 0.75 mm, less than about 0.5 mm, less than about 0.4 mm, less than about 0.3 mm, or less than about 0.2 mm. In various embodiments, the diameter of the aperture or opening through which the dispersed phase is extruded may be greater than about 0.1 mm.
  • the diameter of the aperture or opening through which the dispersed phase is extruded may be greater than about 0.1 mm and less than about 3 mm, greater than about 0.1 mm and less than about 2.5 mm, greater than about 0.1 mm and less than about 2 mm, greater than about 0.1 mm and less than about 1.5 mm, greater than about 0.1 mm and less than about 1 mm, greater than about 0.1 mm and less than about 0.75 mm, greater than about 0.1 mm and less than about 0.5 mm, greater than about 0.1 mm and less than about 0.4 mm, or greater than about 0.1 mm and less than about 0.3 mm.
  • the diameter of the aperture or opening through which the dispersed phase is extruded may be from about 0.1 mm to about 1 mm, from about 1 mm to about 2 mm, or from about 2 mm to about 3 mm.
  • the dispersed phase is extruded through a needle.
  • the needle may be blunt-tipped, although the present disclosure is not limited in this respect.
  • the needle gauge size is 34, 33, 32, 31 , 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 11 , or 10 gauge.
  • the rate of extrusion is not limited and may be controlled using standard laboratory equipment, for example a syringe pump. In various embodiments, the rate of extrusion is less than about 1 mL/min, less than about 100 pL/min, less than about 10 pL/min, less than about 1 pL/min, or less than about 100 nL/min. In other embodiments, the rate of extrusion is from about 1 pL/min to about 1 mL/min, or from about 10 pL/min to about 100 pL/min.
  • the dispersed phase is first extruded through a fluid medium into a mould and then the extruded dispersed phase is contacted with the anti-solvent.
  • the mould may impart a shape to the biopolymer particles formed upon contacting the extruded dispersed phase with the anti-solvent.
  • the shape of the biopolymer particles is not limited, and will be determined by the shape of the mould in this instance.
  • the mould may be formed of any suitable material that is compatible with the dispersed phase and anti-solvent, and may, for example, be a silicone polymer such as polydimethylsiloxane (PDMS).
  • PDMS polydimethylsiloxane
  • the mould may be prepared by casting the mould material, or may be prepared by 3D printing the mould material.
  • the extruded dispersed phase may be contacted with the antisolvent by submerging the mould containing the extruded dispersed phase in the anti-solvent.
  • the mould may be removed after the biopolymer particles have formed, or may be retained during further processing steps, such as washing and filtration/extraction of the biopolymer particles.
  • extrusion may occur within the anti-solvent; that is to say, the dispersed phase may be exposed to the anti-solvent immediately upon extrusion (for example where the aperture or opening is submerged in the anti-solvent).
  • the extruded dispersed phase is dropped from a height above the surface of the anti-solvent. This can be seen in Figure 1 , wherein the extruded dispersed phase is dropped from a height, d, above the surface of the anti-solvent.
  • the dropping height may influence the sphericity of the particles obtained by the extrusion process. Without wishing to be bound by any one theory, it is believed that a greater dropping height may minimize tailing (i.e. improve sphericity) by allowing more time for cohesive forces to act on the falling droplet.
  • the extruded phase is dropped from a height of at least 10 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of at least 20 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of at least 30 cm above the surface of the anti-solvent.
  • the extruded phase is dropped from a height of at least 40 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of at least 50 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of at least 60 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of at least 70 cm above the surface of the anti-solvent, or at least 80 cm above the surface of the anti-solvent.
  • the maximum dropping height will be determined by the distance at which non- spherical particles are formed. This is known in the art and readily understood by the skilled person. It may, for instance, be determined by eye. In various embodiments, however, the extruded phase is dropped from a height of less than 80 cm above the surface of the antisolvent. In various embodiments, the extruded phase is dropped from a height of less than 70 cm above the surface of the anti-solvent. In various embodiments, the extruded phase is dropped from a height of In various embodiments, the extruded phase is dropped from a height of less than 60 cm above the surface of the anti-solvent. In various embodiments, the extruded phase is dropped from a height of less than 50 cm above the surface of the anti-solvent.
  • the extruded phase is dropped from a height of about 1 cm to about 80 cm above the surface of the anti-solvent, preferably from a height of about 5 cm to about 70 cm, more preferably from a height of about 10 cm to about 60 cm.
  • the extruded phase is dropped from a height of about 10 cm to about 80 cm above the surface of the anti-solvent.
  • the extruded phase is dropped from a height of about 10 cm to about 70 cm above the surface of the antisolvent.
  • the extruded phase is dropped from a height of about 10 cm to about 60 cm above the surface of the anti-solvent.
  • the extruded phase is dropped from a height of about 10 cm to about 50 cm above the surface of the antisolvent.
  • the extruded phase is dropped from a height of about 20 cm to about 80 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of about 20 cm to about 70 cm above the surface of the antisolvent. In various embodiments the extruded phase is dropped from a height of about 20 cm to about 60 cm above the surface of the anti-solvent. In various embodiments the extruded phase is dropped from a height of about 20 cm to about 50 cm above the surface of the antisolvent. In various embodiments the extruded phase is dropped from a height of about 20 cm to about 40 cm above the surface of the anti-solvent.
  • the extrusion process may further comprise the step of separating the biopolymer particles from the anti-solvent.
  • the means by which the biopolymer particles may be separated from the anti-solvent are not limited and will be known to a person skilled in the art.
  • the biopolymer particles may be separated from the antisolvent by a filtration process.
  • the filtration process is not limited and may involve mechanical or any other type of filtration (e.g. using equipment known in the art such as a hydrocyclone).
  • a filtration medium e.g. a filter
  • the biopolymer particles may be allowed to settle in a vessel and anti-solvent removed or decanted to leave biopolymer particles wetted in residual antisolvent.
  • the biopolymer particles may be separated by a centrifugal separator or a disk stack separator.
  • the biopolymer particles may be washed one or more times, for example with an aqueous solvent including water. Such washing steps may be performed to remove residual ionic liquid that may be present.
  • the solvent in which the biopolymer particles are immersed may be exchanged for an alternative solvent.
  • membrane emulsification involves passing a dispersed phase through a membrane into a continuous phase so as to form an emulsion.
  • the membrane is not limited; it can be any porous structure suitable for a membrane emulsification process.
  • the membrane may be a plate with holes acting as pores (e.g. micron-sized holes), a perforated metal tube, or sintered porous glass.
  • emulsion is meant the class of two-phase systems of matter where both phases are liquid. Emulsions are a type of colloid, and generally consist of two immiscible liquids. In various embodiments, the emulsion may be a macro-emulsion; this is an emulsion in which the particles of the dispersed phase have diameters of approximately 1 to 1000 microns.
  • sol refers to a general class of two-phase systems of matter where the continuous phase is liquid and the dispersed phase is solid.
  • the membrane emulsification is also not limited and may be any membrane emulsification process known in the art.
  • the membrane emulsification process may be a cross-flow membrane emulsification, a rotational membrane emulsification, a vibrational membrane emulsification, or a combination thereof.
  • cross-flow As is understood in the art, the terms “cross-flow”, “rotational” and “vibrational” refer to the method used to generate shear on the membrane surface.
  • a continuous phase could, for example, move relative to a stationary membrane to create shear, or the membrane could move relative to stationary phases.
  • the dispersed phase could be injected into a stationary continuous phase.
  • the membrane emulsification may involve a cross flow system, a stirred-cell tube membrane, a stirred cell-flat membrane, a rotating flat membrane, a vibrating/rotating tube membrane and/or a premixed membrane emulsification.
  • the membrane emulsification is a cross-flow membrane emulsification.
  • an emulsification process in which the continuous phase moves relative to a stationary membrane is preferred.
  • the dispersed phase and continuous phase will depend on the biopolymer being used.
  • Various features of the solvent for the dispersed phase have already been discussed above, and said features individually or in any combination thereof are combinable with the embodiments disclosed herein.
  • the continuous phase will comprise a solvent which is immiscible with the dispersed phase such that an emulsion is formed when the dispersed phase is forced through the porous membrane.
  • solvent has the meaning as already defined hereinabove.
  • the solvent of the continuous phase is not limited other than it must be immiscible with the dispersed phase.
  • the solvent of the continuous phase may be a non-polar solvent.
  • the solvent of the continuous phase may be selected from hydrocarbon oils and blends thereof. Such hydrocarbon oils may be mineral oils, vegetable oils, or synthetic oils.
  • the solvent of the continuous phase may further comprise water and/or one or more ionic liquids that may be present in residual amounts. Such residues of water and/or ionic liquid may arise as a result of solvent recycling processes.
  • the solvent used for the continuous phase is environmentally friendly. More preferably the solvent used for both the dispersed phase and continuous phase is environmentally friendly.
  • the term “environmentally friendly” has the meaning as already defined hereinabove.
  • the continuous phase may further include optional components.
  • optional components include, but are not limited to, co-solvents, surfactants, pigments, and dyes. The level of any of the optional components is not significant in the present disclosure.
  • the continuous phase includes a co-solvent.
  • the co-solvent is not limited and may be any solvent known in the art.
  • the co-solvent may be selected from hydrocarbon oils and blends thereof.
  • Such hydrocarbon oils may be mineral oils, vegetable oils, or synthetic oils.
  • the co-solvent may further be a co-solvent mixture.
  • the surfactant is as defined above.
  • the emulsion is cooled to a temperature Ti, Ti being greater than the pour point of the continuous phase (T CO nt), and equal to or less than a transition temperature selected from the group consisting of the freezing point, glass transition temperature and pour point, of the dispersed phase (Tdisp): wherein Tdisp > T CO nt.
  • Ti is not, however, critical to the present disclosure; rather it is the relationship of Ti to the respective temperatures of the dispersed phase and continuous phase that is important.
  • pour point refers to the temperature below which a substance (e.g. liquid) loses its flow characteristics. It is typically defined as the minimum temperature at which the liquid (e.g. oil) has the ability to pour down from a beaker.
  • the pour point can be measured with standard methods known in the art. ASTM D7346, Standard Test Method for No Flow Point and Pour Point of Petroleum Products and Liquid Fuels may, for example be used. For commercially available materials, the pour point is often provided by the supplier or manufacturer.
  • freeze point refers to the temperature at which a substance changes state from liquid to solid at standard atmospheric pressure (1 atmosphere).
  • the freezing point can be measured with standard methods known in the art. ASTM E794, Standard Test Method for Melting and Crystallization Temperatures by Thermal Analysis may, for example, be used.
  • ASTM E794 Standard Test Method for Melting and Crystallization Temperatures by Thermal Analysis may, for example, be used.
  • the freezing point may be provided by the supplier or manufacturer.
  • glass transition point or “glass transition temperature” refers to the temperature at which a polymer structure transitions from a hard or glassy material to a soft, rubbery material. This temperature can be measured by differential scanning calorimetry according to the standard test method: ASTM E1356, Standard Test Method for Assignment of the Glass Transition Temperature by Differential Scanning Calorimetry. For commercially available materials, the glass transition temperature may be provided by the supplier or manufacturer.
  • the dispersed phase having a transition temperature - the transition temperature being selected from the group consisting of freezing point, glass transition temperature and pour point - which is higher than the continuous phase pour point means that the continuous phase surrounding the solidified dispersed phase is still able to function as a transport medium.
  • a diagrammatic representation of an emulsion undergoing cooling and temporary conversion to a sol within a cooling coil heat exchanger is shown in Figure 2(b).
  • the method of cooling is not also limited.
  • the emulsion may be cooled by any means known in the art for removing heat (energy) from a system.
  • the emulsion may further be cooled at any point prior to phase inversion. In various embodiments, this means the emulsion is cooled simultaneously with or separately from the membrane emulsification process.
  • the emulsion may, for example, be cooled as it is formed (e.g. by a cooling means located at the outlet of the membrane).
  • the emulsion may be cooled in a step following membrane emulsification, e.g. in a cooling apparatus separate from the membrane emulsification apparatus.
  • the cooling should take place as soon as possible after the emulsification takes place in order to reduce the possibility of liquid state dispersed phase droplets coalescing and/or aggregating.
  • the emulsion may be cooled by a cooling medium (e.g. water, ice etc.) at least partially surrounding the vessel where the emulsion is formed.
  • a cooling medium e.g. water, ice etc.
  • the vessel (e.g. pipe) where the emulsion is formed may have a cooling jacket containing a cooling medium.
  • the cooling medium is not limited, and includes any medium having a lower temperature than the emulsion.
  • the emulsion may be cooled by a cooling apparatus connected to the membrane emulsification unit.
  • the cooling apparatus may be a heat exchanger, such as an immersion heat exchanger.
  • a coil heat exchanger is immersed in a cooling medium (e.g. a cold water bath) but the disclosure is not limited in this respect.
  • Any type of heat exchanger could, for instance, be used such as a tube-and-shell heat exchanger, a plate-and-frame heat exchanger, or a jacketed tube.
  • an immersion heat exchanger could be used with another cooling medium such as anti-freeze, dry ice or the like, in order to cool the emulsion to Ti.
  • phase inversion is carried out under shear; the skilled person will be aware of suitable shear conditions for phase inversion.
  • Shear may, for example, be achieved through the use of a stirred vessel (e.g. a mechanically stirred vessel) or a settling vessel (e.g. a gravity settling vessel).
  • stirred vessel e.g. a mechanically stirred vessel
  • settling vessel e.g. a gravity settling vessel.
  • shear is used herein to refer to an external force acting on an object or surface parallel to the slope or plane in which it lies, the stress tending to produce strain.
  • phase inversion comprises a filtration process.
  • the filtration process is not limited and may involve mechanical or any other type of filtration (e.g. using equipment known in the art such as a hydrocyclone).
  • a filtration process may also be encompassed by the phase inversion being carried out under shear as described above.
  • a filtration medium e.g. filter
  • the emulsion may gravity settle (shear) through the anti-solvent and into the filter, whilst the continuous phase passes through the filter (the filtrate). The frozen droplets may then be collected in the filter as the filter cake.
  • the biopolymer particles may be separated from the anti-solvent/continuous phase mixture or the anti-solvent/continuous phase mixture may be removed from the particles.
  • the method of removal is not limited. In various embodiments, however, the method of removal depends on whether the method is being operated in batch or continuous mode.
  • the phase inversion step may first be performed in a closed vessel and the resulting mixture then transferred into a decanter vessel and allowed to reach a settled stage. Once settled, layers may be removed sequentially from the bottom of the vessel.
  • the order of the layers can be (1) continuous phase, (2) an interfacial layer comprising wetted biopolymer particles and (3) the remaining anti-solvent.
  • the disclosure is not, however, limited in this respect and the skilled person will appreciate that the order of the layers will depend on their respective densities.
  • the method is continuous and to operate in continuous mode
  • the phase inversion step may be performed under continuous input of emulsion and antisolvent and continuous output of the multi-phase mixture to a decanter.
  • a steady-state partition of the mixture may exist and there can be a continuous and preferably simultaneous removal from each of the phases.
  • the order of these layers will of course vary and the method is not limited to any particular order.
  • the multi-phase (e.g. three phase) mixture may be separated using techniques known in the art, such as a disc stack separator (e.g. a centrifugal separator such as the one manufactured by Andritz).
  • a disc stack separator e.g. a centrifugal separator such as the one manufactured by Andritz.
  • the cooling medium e.g. a medium surrounding the vessel containing the emulsion or used with a heat exchanger connected to the membrane emulsification unit
  • the cooling medium may need to be recycled or recirculated with a suitable device.
  • a device such as a recirculating chiller (ThermoFlex available from ThermoFisher Scientific) may, for example, be used to keep the cooling medium at the desired temperature.
  • phase inversion is followed by or involves removal of the biopolymer particles as described above.
  • Phase inversion may be followed by decanting and then biopolymer particle removal from the mixture and/or phase inversion may involve mechanical filtration of the wetted particles from the anti-solvent/continuous phase/particle mixture.
  • the biopolymer particles may be removed from the continuous phase before phase inversion.
  • wetted frozen droplets may be removed from the sol (e.g. using filtration) and then phase inversion carried out to precipitate the biopolymer and form beads/particles thereof.
  • Microcrystalline cellulose (MCC, from Sigma-Aldrich®) and EmimOAc were dried in a vacuum oven at 80°C for 1 h to remove traces of water.
  • Cellulose solutions were prepared at a concentration of 8 wt% MCC in the EmimOAc with 8 wt% deionized water content.
  • the water was first added to the EmimOAc under stirring, followed by the MCC.
  • the mixture was shaken by hand for a minute, then transferred to rollers for 24 h.
  • the samples were placed in a 70°C oven for 24 h, stirred with a spatula, left in the oven for a further 24 h, and then finally transferred to the rollers once again for 24 h.
  • cellulose solutions were prepared by dispersing the MCC in dimethyl sulfoxide (DMSO) with an overhead stirrer (900 rpm) at room temperature before EmimOAc was added dropwise into the dispersion and the mixture was stirred for 4 h.
  • DMSO dimethyl sulfoxide
  • EmimOAc was added dropwise into the dispersion and the mixture was stirred for 4 h.
  • the solvent ratio of DMSO to EmimOAc was 70:30 w/w.
  • a dispersed phase comprising 8 wt% microcrystalline cellulose and 8 wt% water in 1- ethyl-3-methylimidazolium acetate was prepared according to routine methods known in the art. This dispersed phase had a transition temperature (e.g. freezing point) of approximately -5°C.
  • An aqueous continuous phase was also prepared according to routine methods known in the art. The continuous phase had a pour point of -15°C.
  • the dispersed phase and continuous phase were fed into a membrane emulsification unit and an emulsion thereby formed.
  • the emulsion was then cooled to a temperature between 0 and 11 °C before being transferred into a phase inversion unit with an aqueous anti-solvent to form cellulose particles.
  • Cooling of the emulsion was carried out with an immersed coil heat exchanger. The immersed coil heat exchanger was chosen to maintain a laminar flow and minimise flow disturbances as the emulsion cooled.
  • the coil heat exchanger contained a length (L) of coiled tubing with diameter D and pitch P, in a cold water bath at 0°C and was sufficient to cool a 0.5 L/min emulsion to below 11 °C. The temperature of the emulsion was monitored with a thermometer at the exit of the coil heat exchanger. Spherical biopolymer particles were thereby obtained.
  • cellulose beads were prepared from an 8 wt% cellulose solution according to the methods detailed above.
  • the cellulose beads (10 g) were suspended in 40 mL of sodium periodate at a concentration of 50 mM and the reaction was allowed to proceed at 20 °C for 3.5 h under mild agitation using an overhead stirrer. Subsequently, the sodium periodate was removed by separating the beads using a stainless-steel sieve and washed with deionised water until the absorption of the supernatant at 290 nm (corresponding to the absorption peak of sodium periodate) was zero. The washed beads were then stored in deionised water at room temperature.
  • the degree of oxidation of the oxidised beads was determined to be approximately 10% (based on the number of moles of carbonyl groups per mole of anhydrous glucose units [AUG]) by the method of reaction with hydroxylamine hydrochloride and titration with sodium hydroxide as detailed herein.
  • Aminated cellulose beads were prepared using 1 ,6-diaminohexane or 1 ,8- diaminooctane as detailed in Example 2, except that the steps of reaction with the diamine and subsequent reduction with sodium borohydride were each performed in deionised water. 1.5 mole equivalents of sodium borohydride were used to compensate for the reduced stability of the sodium borohydride in water.
  • reaction scheme can be depicted as set out below: where ‘DAC’ refers to dialdehyde cellulose, and ‘DABs’ refers to diaminated beads.
  • Enzyme activity was determined in vitro by measuring the conversion over time of p- nitrophenyl butyrate to p-nitrophenol and butyric acid by UV-vis spectrophotometry.
  • the reaction scheme for the assay is shown below: p-Nitrophenyl butyrate Water Butyric acid p-nitrophenol Hydrogen
  • a oonm absorbance (final) - absorbance (initial);
  • aminated beads in the form of a hydrogel as prepared by the methods detailed above and which had been stored in water were freeze-dried in a lyophiliser before being imaged by SEM.
  • Micrographs were obtained using a JEOL SEM648OLV microscope.
  • the samples were flash frozen in liquid nitrogen and lyophilized using a MiniLyotrap (LTE scientific).
  • Cross sections were prepared by cutting with sharp blades before the flash freezing process. Prior to imaging, the samples were gold coated (Edwards sputter coater, S150B) for 5 min.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La présente invention concerne des procédés de préparation de particules de biopolymère fonctionnalisées. Un aspect concerne un procédé comprenant l'oxydation de particules de biopolymère pour former des particules de biopolymère oxydées, le degré d'oxydation des particules de biopolymère oxydées étant inférieur ou égal à environ 25 % ; et la réaction desdites particules de biopolymère oxydées avec un composé comprenant une ou plusieurs fractions hydrophobes. L'invention concerne également des particules de biopolymère fonctionnalisées obtenues à partir des procédés ainsi que leurs utilisations.
PCT/GB2023/050786 2022-03-29 2023-03-27 Préparation de particules de biopolymère fonctionnalisées WO2023187348A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2204453.1 2022-03-29
GBGB2204453.1A GB202204453D0 (en) 2022-03-29 2022-03-29 Functionalised biopolymer particle preparation

Publications (1)

Publication Number Publication Date
WO2023187348A1 true WO2023187348A1 (fr) 2023-10-05

Family

ID=81449427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2023/050786 WO2023187348A1 (fr) 2022-03-29 2023-03-27 Préparation de particules de biopolymère fonctionnalisées

Country Status (2)

Country Link
GB (1) GB202204453D0 (fr)
WO (1) WO2023187348A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045830A1 (fr) 1999-12-22 2001-06-28 University Of Leeds Membrane de rotation
WO2012094595A2 (fr) 2011-01-07 2012-07-12 Brotech Corp., D/B/A Purolite Procédé de production de billes polymères uniformes de taille variée
WO2019092461A1 (fr) 2017-11-13 2019-05-16 Micropore Technologies Ltd Ensemble à écoulement transversal pour production de gouttelettes commandée par émulsification par membrane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045830A1 (fr) 1999-12-22 2001-06-28 University Of Leeds Membrane de rotation
WO2012094595A2 (fr) 2011-01-07 2012-07-12 Brotech Corp., D/B/A Purolite Procédé de production de billes polymères uniformes de taille variée
WO2019092461A1 (fr) 2017-11-13 2019-05-16 Micropore Technologies Ltd Ensemble à écoulement transversal pour production de gouttelettes commandée par émulsification par membrane

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACS SUSTAINABLE CHEM. ENG., vol. 5, no. 7, 2017, pages 5931 - 5939
LE GARS MANON ET AL: "Amidation of TEMPO-oxidized cellulose nanocrystals using aromatic aminated molecules", COLLOID & POLYMER SCIENCE, SPRINGER VERLAG, HEIDELBERG, DE, vol. 298, no. 6, 13 April 2020 (2020-04-13), pages 603 - 617, XP037143937, ISSN: 0303-402X, [retrieved on 20200413], DOI: 10.1007/S00396-020-04640-5 *
NIKOLIC TANJA ET AL: "Preparation of cellulosic fibers with biological activity by immobilization of trypsin on periodate oxidized viscose fibers", CELLULOSE, vol. 21, no. 3, 1 June 2014 (2014-06-01), Netherlands, pages 1369 - 1380, XP055871969, ISSN: 0969-0239, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s10570-014-0171-0.pdf> DOI: 10.1007/s10570-014-0171-0 *
OBRIEN JAMES COOMBS ET AL: "Continuous Production of Cellulose Microbeads via Membrane Emulsification", ACS SUSTAINABLE CHEM. ENG., vol. 5, 31 May 2017 (2017-05-31), pages 5931 - 5939, XP055979096 *
PEDRO S. SILVA ET AL.: "Azimuthally Oscillating Membrane Emulsification for Controlled Droplet Production", AICHE JOURNAL, vol. 00, no. 00, 2015
RICHARD ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 4974 - 4975
VERMA ET AL., SUSTAINABLE CHEMISTRY AND PHARMACY, vol. 13, 2019, pages 100162
WILLIAMS ET AL., THERMOCHIMICA ACTA, vol. 669, 2018, pages 126 - 139

Also Published As

Publication number Publication date
GB202204453D0 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
Pagliano et al. Recovery of polyhydroxyalkanoates from single and mixed microbial cultures: A review
Ganesan et al. Review on the production of polysaccharide aerogel particles
Gericke et al. Functional cellulose beads: preparation, characterization, and applications
Beisl et al. Lignin from micro-to nanosize: production methods
JP5600333B2 (ja) ポリマー抽出法
Yoo et al. Green one-pot synthesis of surface hydrophobized cellulose nanocrystals in aqueous medium
Iskak et al. Understanding the effect of synthesis parameters on the catalytic ionic liquid hydrolysis process of cellulose nanocrystals
FR2947553A1 (fr) Esters gras de cellulose, procede de synthese et utilisations
JP2008104359A (ja) 酵素固定用担体、固定化酵素および酵素固定用担体の製造方法
AU2005285271A1 (en) Single solvent polymer extraction methods
Zhang et al. Effects of dehydration rate on the yield of ethyl lactate in a pervaporation-assisted esterification process
Simon et al. Cellulase immobilization on poly (methyl methacrylate) nanoparticles by miniemulsion polymerization
Gupta Comparative study on hydrolysis of oils by lipase immobilized biocatalytic PS membranes using biphasic enzyme membrane reactor
WO2023187348A1 (fr) Préparation de particules de biopolymère fonctionnalisées
Andler et al. Influence of hierarchical interfacial assembly on lipase stability and performance in deep eutectic solvent
Gözke et al. Electrofiltration of biopolymers
Shen et al. Acidified ZnCl2 molten salt hydrate systems as hydrolytic media for cellulose I and II nanocrystal production: from rods to spheres
Wenger et al. Systematic evaluation of agarose-and agar-based bioinks for extrusion-based bioprinting of enzymatically active hydrogels
Shahnawaz et al. Pickering emulsions for the polymerization of ε-caprolactone in continuous flow process
Wu et al. Recyclable biomass-derived polyethylene-like materials as functional coatings for commercial fabrics: Toward Upcycling of waste textiles
Ariffin et al. Surfactant Synthesis via Lipase Esterification of Methyl α‐d‐Glucopyranoside with Selected Aliphatic Carboxylic Acids
WO2023052744A1 (fr) Particules de biopolymère et leur préparation
XiaoYan et al. Lipase‐catalyzed esterification of konjac glucomannan in isooctane
Ugur Nigiz et al. Rhizomucor miehei lipase-immobilized sodium alginate membrane preparation and usage in a pervaporation biocatalytic membrane reactor
WO2020239983A1 (fr) Particules de polymère lipolytique pour estérification et interestérification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23715915

Country of ref document: EP

Kind code of ref document: A1